Frizzled homolog proteins, microRNAs and Wnt signaling in cancer

International Journal of Cancer

Volumn 132, Issue 8, 2013, Pages 1731-1740

  Ueno, Koji ^a   Hirata, Hiroshi ^a   Hinoda, Yuji ^b   Dahiya, Rajvir ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

cancer; FZD; microRNA; Wnt signaling

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BETA CATENIN; DISHEVELLED PROTEIN; DOXORUBICIN; FRIZZLED PROTEIN; MICRORNA;

3' UNTRANSLATED REGION; CANCER CELL CULTURE; CARCINOGENESIS; CELL PROLIFERATION; DOWN REGULATION; FZD GENE; FZD1 GENE; FZD10 GENE; FZD2 GENE; FZD3 GENE; FZD4 GENE; FZD5 GENE; FZD6 GENE; FZD7 GENE; FZD8 GENE; FZD9 GENE; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MAPPING; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; UPREGULATION; WNT SIGNALING PATHWAY;

FRIZZLED RECEPTORS; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICRORNAS; NEOPLASMS; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 84873998813     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27746     Document Type: Review

References (159)

1. Huang HC, Klein PS,. The Frizzled family: receptors for multiple signal transduction pathways. Genome Biol 2004; 5: 234.
2. Moon RT, Kohn AD, De Ferrari GV, et al. WNT and beta-catenin signaling: diseases and therapies. Nat Rev Genet 2004; 5: 691-701.
3. Clevers H,. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127: 469-80.
4. Katoh M, Katoh M,. WNT signaling pathway and stem cell signaling network. Clin Cancer Res 2007; 13: 4042-5.
5. Lai SL, Chien AJ, Moon RT,. Wnt/Fz signaling and the cytoskeleton: potential roles in tumorigenesis. Cell Res 2009; 19: 532-45.
6. Cohen ED, Tian Y, Morrisey EE,. Wnt signaling: an essential regulator of cardiovascular differentiation, morphogenesis and progenitor self-renewal. Development 2008; 135: 789-98.
7. Golan T, Yaniv A, Bafico A, et al. The human Frizzled 6 (HFz6) acts as a negative regulator of the canonical Wnt. beta-catenin signaling cascade. J Biol Chem 2004; 279: 14879-88.
8. Marinissen MJ, Chiariello M, Tanos T, et al. The small GTP-binding protein RhoA regulates c-jun by a ROCK-JNK signaling axis. Mol Cell 2004; 14: 29-41.
9. Fukukawa C, Nagayama S, Tsunoda T, et al. Activation of the non-canonical Dvl-Rac1-JNK pathway by Frizzled homologue 10 in human synovial sarcoma. Oncogene 2009; 28: 1110-20.
10. Ueno K, Hazama S, Mitomori S, et al. Down-regulation of frizzled-7 expression decreases survival, invasion and metastatic capabilities of colon cancer cells. Br J Cancer 2009; 101: 1374-81.
11. Ying SY, Chang DC, Lin SL,. The microRNA (miRNA): overview of the RNA genes that modulate gene function. Mol Biotechnol 2008; 38: 257-68.
12. Esteller M,. Non-coding RNAs in human disease. Nat Rev Genet 2011; 12: 861-74.
13. McManus MT, Sharp PA,. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002; 3: 737-47.
14. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-8.
15. Esquela-Kerscher A, Slack FJ,. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-69.
16. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-61.
17. Sagara N, Toda G, Hirai M, et al. Molecular cloning, differential expression, and chromosomal localization of human frizzled-1, frizzled-2, and frizzled-7. Biochem Biophys Res Commun 1998; 252: 117-22.
18. Gazit A, Yaniv A, Bafico A, et al. Human frizzled 1 interacts with transforming Wnts to transduce a TCF dependent transcriptional response. Oncogene 1999; 18: 5959-66.
19. Holcombe RF, Marsh JL, Waterman ML, et al. Expression of Wnt ligands and Frizzled receptors in colonic mucosa and in colon carcinoma. Mol Pathol 2002; 55: 220-6.
20. Badiglian Filho L, Oshima CT, De Oliveira Lima F, et al. Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer. Oncol Rep 2009; 21: 313-20.
21. Milovanovic T, Planutis K, Nguyen A, et al. Expression of Wnt genes and frizzled 1 and 2 receptors in normal breast epithelium and infiltrating breast carcinoma. Int J Oncol 2004; 25: 1337-42.
22. Flahaut M, Meier R, Coulon A, et al. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway. Oncogene 2009; 28: 2245-56.
23. Wang PS, Chou FS, Bloomston M, et al. Thiazolidinediones downregulate Wnt/beta-catenin signaling via multiple mechanisms in breast cancer cells. J Surg Res 2009; 153: 210-6.
24. Flahaut M, Mühlethaler-Mottet A, Martinet D, et al. Molecular cytogenetic characterization of doxorubicin-resistant neuroblastoma cell lines: evidence that acquired multidrug resistance results from a unique large amplification of the 7q21 region. Genes Chromosomes Cancer 2006; 45: 495-508.
25. Ulivieri A, Lavra L, Dominici R, et al. Frizzled-1 is down-regulated in follicular thyroid tumours and modulates growth and invasiveness. J Pathol 2008; 215: 87-96.
26. Li G, Luna C, Qiu J, et al. Alterations in microRNA expression in stress-induced cellular senescence. Mech Ageing Dev 2009; 130: 731-41.
27. Li G, Luna C, Qiu J, et al. Modulation of inflammatory markers by miR-146a during replicative senescence in trabecular meshwork cells. Invest Ophthalmol Vis Sci 2010; 51: 2976-85.
28. Li G, Luna C, Qiu J, et al. Role of miR-204 in the regulation of apoptosis, endoplasmic reticulum stress response, and inflammation in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 2011; 52: 2999-3007.
29. Chung TK, Lau TS, Cheung TH, et al. Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1. Int J Cancer 2012; 130: 1036-45.
30. Lee Y, Yang X, Huang Y, et al. Network modeling identifies molecular functions targeted by miR-204 to suppress head and neck tumor metastasis. PLoS Comput Biol 2010; 6: e1000730.
31. White NM, Khella HW, Grigull J, et al. miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. Br J Cancer 2011; 105: 1741-9.
32. Zhao Z, Lee CC, Baldini A, et al. A human homologue of the Drosophila polarity gene frizzled has been identified and mapped to 17q21.1. Genomics 1995; 27: 370-3.
33. Pode-Shakked N, Metsuyanim S, Rom-Gross E, et al. Developmental tumourigenesis: NCAM as a putative marker for the malignant renal stem/progenitor cell population. J Cell Mol Med 2009; 13: 1792-808.
34. Rhee CS, Sen M, Lu D, et al. Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas. Oncogene 2002; 21: 6598-605.
35. Bazhin AV, Tambor V, Dikov B, et al. cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca(2+) homeostasis in melanoma cells. Cell Mol Life Sci 2010; 67: 817-28.
36. Lee EH, Chari R, Lam A, et al. Disruption of the non-canonical WNT pathway in lung squamous cell carcinoma. Clin Med Oncol 2008; 2008: 169-79.
37. Li C, Chen H, Hu L, et al. Ror2 modulates the canonical Wnt signaling in lung epithelial cells through cooperation with Fzd2. BMC Mol Biol 2008; 9: 11.
38. Kirikoshi H, Koike J, Sagara N, et al. Molecular cloning and genomic structure of human frizzled-3 at chromosome 8p21. Biochem Biophys Res Commun 2000; 271: 8-14.
39. Sala CF, Formenti E, Terstappen GC, et al. Identification, gene structure, and expression of human frizzled-3 (FZD3). Biochem Biophys Res Commun 2000; 273: 27-34.
40. Tapper J, Kettunen E, El-Rifai W, et al. Changes in gene expression during progression of ovarian carcinoma. Cancer Genet Cytogenet 2001; 128: 1-6.
41. Khan NI, Bradstock KF, Bendall LJ,. Activation of Wnt/beta-catenin pathway mediates growth and survival in B-cell progenitor acute lymphoblastic leukaemia. Br J Haematol 2007; 138: 338-48.
42. Qiang YW, Endo Y, Rubin JS, et al. Wnt signaling in B-cell neoplasia. Oncogene 2003; 22: 1536-45.
43. Reins J, Mossner M, Neumann M, et al. Transcriptional down-regulation of the Wnt antagonist SFRP1 in haematopoietic cells of patients with different risk types of MDS. Leuk Res 2010; 34: 1610-6.
44. Caldwell GM, Jones CE, Ashley AM, et al. Wnt signaling in adenomas of familial adenomatous polyposis patients. Br J Cancer 2010; 103: 910-7.
45. Lu D, Zhao Y, Tawatao R, et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2004; 101: 3118-23.
46. Endo Y, Beauchamp E, Woods D, et al. Wnt-3a and Dickkopf-1 stimulate neurite outgrowth in Ewing tumor cells via a Frizzled3- and c-Jun N-terminal kinase-dependent mechanism. Mol Cell Biol 2008; 28: 2368-79.
47. Hansen C, Howlin J, Tengholm A, et al. Wnt-5a-induced phosphorylation of DARPP-32 inhibits breast cancer cell migration in a CREB-dependent manner. J Biol Chem 2009; 284: 27533-43.
48. Valastyan S, Reinhardt F, Benaich N, et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009; 137: 1032-46.
49. Kirikoshi H, Sagara N, Koike J, et al. Molecular cloning and characterization of human Frizzled-4 on chromosome 11q14-q21. Biochem Biophys Res Commun 1999; 264: 955-61.
50. Sagara N, Kirikoshi H, Terasaki H, et al. FZD4S, a splicing variant of frizzled-4, encodes a soluble-type positive regulator of the WNT signaling pathway. Biochem Biophys Res Commun 2001; 282: 750-6.
51. Swain RK, Katoh M, Medina A, et al. Xenopus frizzled-4S, a splicing variant of Xfz4 is a context-dependent activator and inhibitor of Wnt/beta-catenin signaling. Cell Commun Signal 2005; 3: 12.
52. Gupta S, Iljin K, Sara H, et al. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 2010; 70: 6735-45.
53. Jin X, Jeon HY, Joo KM, et al. Frizzled 4 regulates stemness and invasiveness of migrating glioma cells established by serial intracranial transplantation. Cancer Res 2011; 71: 3066-75.
54. Dai W, Teodoridis JM, Zeller C, et al. Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clin Cancer Res 2011; 17: 4052-62.
55. Ueno K, Hirata H, Majid S, et al. Tumor suppressor microRNA-493 decreases cell motility and migration ability in human bladder cancer cells by downregulating RhoC and FZD4. Mol Cancer Ther 2012; 11: 244-53.
56. Saitoh T, Hirai M, Katoh M,. Molecular cloning and characterization of human Frizzled-5 gene on chromosome 2q33.3-q34 region. Int J Oncol 2001; 19: 105-10.
57. Janssens N, Andries L, Janicot M, et al. Alteration of frizzled expression in renal cell carcinoma. Tumour Biol 2004; 25: 161-71.
58. Thiele S, Rauner M, Goettsch C, et al. Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates. J Cell Biochem 2011; 112: 1593-600.
59. Weeraratna AT, Jiang Y, Hostetter G, et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 2002; 1: 279-88.
60. Carmon KS, Loose DS,. Wnt7a interaction with Fzd5 and detection of signaling activation using a split eGFP. Biochem Biophys Res Commun 2008; 368: 285-91.
61. Carmon KS, Loose DS,. Secreted frizzled-related protein 4 regulates two Wnt7a signaling pathways and inhibits proliferation in endometrial cancer cells. Mol Cancer Res 2008; 6: 1017-28.
62. Yoshioka S, King ML, Ran S, et al. WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/β-catenin pathway. Mol Cancer Res 2012; 10: 469-82.
63. Tokuhara M, Hirai M, Atomi Y, et al. Molecular cloning of human Frizzled-6. Biochem Biophys Res Commun 1998; 243: 622-7.
64. Haider AS, Peters SB, Kaporis H, et al. Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia. J Invest Dermatol 2006; 126: 869-81.
65. Saramäki OR, Porkka KP, Vessella RL, et al. Genetic aberrations in prostate cancer by microarray analysis. Int J Cancer 2006; 119: 1322-9.
66. Cantilena S, Pastorino F, Pezzolo A, et al. Frizzled receptor 6 marks rare, highly tumourigenic stem-like cells in mouse and human neuroblastomas. Oncotarget 2011; 2: 976-83.
67. Lyons JP, Mueller UW, Ji H, et al. Wnt-4 activates the canonical beta-catenin-mediated Wnt pathway and binds Frizzled-6 CRD: functional implications of Wnt/beta-catenin activity in kidney epithelial cells. Exp Cell Res 2004; 298: 369-87.
68. Heinonen KM, Vanegas JR, Lew D, et al. Wnt4 enhances murine hematopoietic progenitor cell expansion through a planar cell polarity-like pathway. PLoS One 2011; 6: e19279.
69. Miyakoshi T, Takei M, Kajiya H, et al. Expression of Wnt4 in human pituitary adenomas regulates activation of the beta-catenin-independent pathway. Endocr Pathol 2008; 19: 261-73.
70. Krützfeldt J, Rösch N, Hausser J, et al. MicroRNA-194 is a target of transcription factor 1 (Tcf1, HNF1α) in adult liver and controls expression of frizzled-6. Hepatology 2012; 55: 98-107.
71. Tanaka S, Akiyoshi T, Mori M, et al. A novel frizzled gene identified in human esophageal carcinoma mediates APC/beta-catenin signals. Proc Natl Acad Sci USA 1998; 95: 10164-9.
72. Kirikoshi H, Sekihara H, Katoh M,. Up-regulation of Frizzled-7 (FZD7) in human gastric cancer. Int J Oncol 2001; 19: 111-5.
73. Zeng ZY, Zhou YH, Zhang WL, et al. Gene expression profiling of nasopharyngeal carcinoma reveals the abnormally regulated Wnt signaling pathway. Hum Pathol 2007; 38: 120-33.
74. Frierson HF, Jr., El-Naggar AK, Welsh JB, et al. Large scale molecular analysis identifies genes with altered expression in salivary adenoid cystic carcinoma. Am J Pathol 2002; 161: 1315-23.
75. Ueno K, Hiura M, Suehiro Y, et al. Frizzled-7 as a potential therapeutic target in colorectal cancer. Neoplasia 2008; 10: 697-705.
76. Merle P, de la Monte S, Kim M, et al. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology 2004; 127: 1110-22.
77. Merle P, Kim M, Herrmann M, et al. Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. J Hepatol 2005; 43: 854-62.
78. Bengochea A, de Souza MM, Lefrançois L, et al. Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer 2008; 99: 143-50.
79. Schmuck R, Warneke V, Behrens HM, et al. Genotypic and phenotypic characterization of side population of gastric cancer cell lines. Am J Pathol 2011; 178: 1792-804.
80. Yang L, Wu X, Wang Y, et al. FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene 2011; 30: 4437-46.
81. Kim M, Lee HC, Tsedensodnom O, et al. Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol 2008; 48: 780-91.
82. Vincan E, Darcy PK, Smyth MJ, et al. Frizzled-7 receptor ectodomain expression in a colon cancer cell line induces morphological change and attenuates tumor growth. Differentiation 2005; 73: 142-53.
83. Vincan E, Darcy PK, Farrelly CA, et al. Frizzled-7 dictates three-dimensional organization of colorectal cancer cell carcinoids. Oncogene 2007; 26: 2340-52.
84. Vincan E, Flanagan DJ, Pouliot N, et al. Variable FZD7 expression in colorectal cancers indicates regulation by the tumour microenvironment. Dev Dyn 2010; 239: 311-7.
85. Nishioka M, Ueno K, Hazama S, et al. Possible involvement of Wnt11 in colorectal cancer progression. Mol Carcinog [Epub ahead of print].
86. Fujii N, You L, Xu Z, et al. An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. Cancer Res 2007; 67: 573-9.
87. Nambotin SB, Lefrancois L, Sainsily X, et al. Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma. J Hepatol 2011; 54: 288-99.
88. Zhang H, Hao Y, Yang J, et al. Genome-wide functional screening of miR-23b as a pleiotropic modulator suppressing cancer metastasis. Nat Commun 2011; 2: 554.
89. Tong AW, Fulgham P, Jay C, et al. MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 2009; 16: 206-16.
90. Salvi A, Sabelli C, Moncini S, et al. MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells. FEBS J 2009; 276: 2966-82.
91. Saitoh T, Hirai M, Katoh M,. Molecular cloning and characterization of human Frizzled-8 gene on chromosome 10p11.2. Int J Oncol 2001; 18: 991-6.
92. Wang HQ, Xu ML, Ma J, et al. Frizzled-8 as a putative therapeutic target in human lung cancer. Biochem Biophys Res Commun 2012; 417: 62-6.
93. Bourhis E, Tam C, Franke Y, et al. Reconstitution of a frizzled8.Wnt3a.LRP6 signaling complex reveals multiple Wnt and Dkk1 binding sites on LRP6. J Biol Chem 2010; 285: 9172-9.
94. Wang YK, Samos CH, Peoples R, et al. A novel human homologue of the Drosophila frizzled wnt receptor gene binds wingless protein and is in the Williams syndrome deletion at 7q11.23. Hum Mol Genet 1997; 6: 465-72.
95. Wang YK, Spörle R, Paperna T, et al. Characterization and expression pattern of the frizzled gene Fzd9, the mouse homolog of FZD9 which is deleted in Williams-Beuren syndrome. Genomics 1999; 57: 235-48.
96. Zhang Z, Schittenhelm J, Guo K, et al. Upregulation of frizzled 9 in astrocytomas. Neuropathol Appl Neurobiol 2006; 32: 615-24.
97. Martinez R, Martin-Subero JI, Rohde V, et al. A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics 2009; 4: 255-64.
98. Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009; 113: 1315-25.
99. Winn RA, Marek L, Han SY, et al. Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation. J Biol Chem 2005; 280: 19625-34.
100. Winn RA, Van Scoyk M, Hammond M, et al. Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor gamma. J Biol Chem 2006; 281: 26943-50.
101. Tennis MA, Van Scoyk MM, Freeman SV, et al. Sprouty-4 inhibits transformed cell growth, migration and invasion, and epithelial-mesenchymal transition, and is regulated by Wnt7A through PPARgamma in non-small cell lung cancer. Mol Cancer Res 2010; 8: 833-43.
102. Fujimoto T, Tomizawa M, Yokosuka O,. SiRNA of frizzled-9 suppresses proliferation and motility of hepatoma cells. Int J Oncol 2009; 35: 861-6.
103. Koike J, Takagi A, Miwa T, et al. Molecular cloning of Frizzled-10, a novel member of the Frizzled gene family. Biochem Biophys Res Commun 1999; 262: 39-43.
104. Terasaki H, Saitoh T, Shiokawa K, et al. Frizzled-10, up-regulated in primary colorectal cancer, is a positive regulator of the WNT-beta-catenin-TCF signaling pathway. Int J Mol Med 2002; 9: 107-12.
105. Nagayama S, Yamada E, Kohno Y, et al. Inverse correlation of the up-regulation of FZD10 expression and the activation of beta-catenin in synchronous colorectal tumors. Cancer Sci 2009; 100: 405-12.
106. Gugger M, White R, Song S, et al. GPR87 is an overexpressed G-protein coupled receptor in squamous cell carcinoma of the lung. Dis Markers 2008; 24: 41-50.
107. Nagayama S, Fukukawa C, Katagiri T, et al. Therapeutic potential of antibodies against FZD 10, a cell-surface protein, for synovial sarcomas. Oncogene 2005; 24: 6201-12.
108. Togashi A, Katagiri T, Ashida S, et al. Hypoxia-inducible protein 2 (HIG2), a novel diagnostic marker for renal cell carcinoma and potential target for molecular therapy. Cancer Res 2005; 65: 4817-26.
109. Fukukawa C, Hanaoka H, Nagayama S, et al. Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10. Cancer Sci 2008; 99: 432-40.
110. Kikuchi A, Yamamoto H, Kishida S,. Multiplicity of the interactions of Wnt proteins and their receptors. Cell Signal 2007; 19: 659-71.
111. Schulte G,. International union of basic and clinical pharmacology. LXXX. The class Frizzled receptors. Pharmacol Rev 2010; 62: 632-67.
112. Mao B, Wu W, Li Y, et al. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 2001; 411: 321-5.
113. Liu G, Bafico A, Harris VK, et al. A novel mechanism for Wnt activation of canonical signaling through the LRP6 receptor. Mol Cell Biol 2003; 23: 5825-35.
114. Schweizer L, Varmus H,. Wnt/Wingless signaling through beta-catenin requires the function of both LRP/Arrow and frizzled classes of receptors. BMC Cell Biol 2003; 4: 4.
115. Cong F, Schweizer L, Varmus H,. Wnt signals across the plasma membrane to activate the beta-catenin pathway by forming oligomers containing its receptors, Frizzled and LRP. Development 2004; 131: 5103-15.
116. Lindvall C, Evans NC, Zylstra CR, et al. The Wnt signaling receptor Lrp5 is required for mammary ductal stem cell activity and Wnt1-induced tumorigenesis. J Biol Chem 2006; 281: 35081-7.
117. Li Y, Lu W, He X, et al. LRP6 expression promotes cancer cell proliferation and tumorigenesis by altering beta-catenin subcellular distribution. Oncogene 2004; 23: 9129-35.
118. Björklund P, Akerström G, Westin G,. An LRP5 receptor with internal deletion in hyperparathyroid tumors with implications for deregulated WNT/beta-catenin signaling. PLoS Med 2007; 4: e328.
119. Hoang BH, Kubo T, Healey JH, et al. Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 2004; 109: 106-11.
120. Liu CC, Prior J, Piwnica-Worms D, et al. LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. Proc Natl Acad Sci USA 2010; 107: 5136-41.
121. Björklund P, Svedlund J, Olsson AK, et al. The internally truncated LRP5 receptor presents a therapeutic target in breast cancer. PLoS One 2009; 4: e4243.
122. DiMeo TA, Anderson K, Phadke P, et al. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res 2009; 69: 5364-73.
123. Ettenberg SA, Charlat O, Daley MP, et al. Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies. Proc Natl Acad Sci USA 2010; 107: 15473-8.
124. Gong Y, Bourhis E, Chiu C, et al. Wnt isoform-specific interactions with coreceptor specify inhibition or potentiation of signaling by LRP6 antibodies. PLoS One 2010; 5: e12682.
125. Berndt JD, Aoyagi A, Yang P, et al. Mindbomb 1, an E3 ubiquitin ligase, forms a complex with RYK to activate Wnt/β-catenin signaling. J Cell Biol 2011; 194: 737-50.
126. Hovens CM, Stacker SA, Andres AC, et al. RYK, a receptor tyrosine kinase-related molecule with unusual kinase domain motifs. Proc Natl Acad Sci USA 1992; 89: 11818-22.
127. Lu W, Yamamoto V, Ortega B, et al. Mammalian Ryk is a Wnt coreceptor required for stimulation of neurite outgrowth. Cell 2004; 119: 97-108.
128. Kim GH, Her JH, Han JK,. Ryk cooperates with Frizzled 7 to promote Wnt11-mediated endocytosis and is essential for Xenopus laevis convergent extension movements. J Cell Biol 2008; 182: 1073-82.
129. Diaz MO, Ziemin S, Le Beau MM, et al. Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines. Proc Natl Acad Sci USA 1988; 85: 5259-63.
130. Laï JL, Fenaux P, Pollet JP, et al. Acute lymphocytic leukemia with 9p anomalies. A report of four additional cases and review of the literature. Cancer Genet Cytogenet 1988; 33: 99-109.
131. Ountain JW, Karayiorgou M, Ernstoff MS, et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA 1992; 89: 10557-61.
132. Wang XC, Katso R, Butler R, et al. H-RYK, an unusual receptor kinase: isolation and analysis of expression in ovarian cancer. Mol Med 1996; 2: 189-203.
133. Katso RM, Manek S, Ganjavi H, et al. Overexpression of H-Ryk in epithelial ovarian cancer: prognostic significance of receptor expression. Clin Cancer Res 2000; 6: 3271-81.
134. Micci F, Panagopoulos I, Haugom L, et al. t(3;21)(q22;q22) leading to truncation of the RYK gene in atypical chronic myeloid leukemia. Cancer Lett 2009; 277: 205-11
135. Masiakowski P, Carroll RD,. A novel family of cell surface receptors with tyrosine kinase-like domain. J Biol Chem 1992; 267: 26181-90.
136. Li C, Chen H, Hu L, et al. Ror2 modulates the canonical Wnt signaling in lung epithelial cells through cooperation with Fzd2. BMC Mol Biol 2008; 9: 11.
137. Enomoto M, Hayakawa S, Itsukushima S, et al. Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene 2009; 28: 3197-208.
138. Wright TM, Brannon AR, Gordan JD, et al. Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma. Oncogene 2009; 28: 2513-23.
139. Yamamoto H, Oue N, Sato A, et al. Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase. Oncogene 2010; 29: 2036-46.
140. O'Connell MP, Fiori JL, Xu M, et al. The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene 2010; 29: 34-44.
141. Edris B, Espinosa I, Mühlenberg T, et al. ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. J Pathol 2012; 227: 223-33.
142. Kawano Y, Kypta R,. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003; 116: 2627-34.
143. Roth W, Wild-Bode C, Platten M, et al. Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. Oncogene 2000; 19: 4210-20.
144. Suzuki H, Watkins DN, Jair KW, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004; 36: 417-22.
145. Nozaki I, Tsuji T, Iijima O, et al. Reduced expression of REIC/Dkk-3 gene in non-small cell lung cancer. Int J Oncol 2001; 19: 117-21.
146. Kobayashi K, Ouchida M, Tsuji T, et al. Reduced expression of the REIC/Dkk-3 gene by promoter-hypermethylation in human tumor cells. Gene 2002; 282: 151-8.
147. Wissmann C, Wild PJ, Kaiser S, et al. WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 2003; 201: 204-12.
148. Mazieres J, He B, You L, et al. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 2004; 64: 4717-20.
149. Ilyas M, Tomlinson IP,. The interactions of APC, E-cadherin and beta-catenin in tumour development and progression. J Pathol 1997; 182: 128-37.
150. Miyao N, Tsai YC, Lerner SP, et al. Role of chromosome 9 in human bladder cancer. Cancer Res 1993; 53: 4066-70.
151. Taguchi T, Jhanwar SC, Siegfried JM, et al. Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res 1993; 53: 4349-55.
152. Osborne RJ, Leech V,. Polymerase chain reaction allelotyping of human ovarian cancer. Br J Cancer 1994; 69: 429-38.
153. Fujino T, Risinger JI, Collins NK, et al. Allelotype of endometrial carcinoma. Cancer Res 1994; 54: 4294-8.
154. Hanaoka H, Katagiri T, Fukukawa C, et al. Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10: therapeutic efficacy largely depends on radiosensitivity. Ann Nucl Med 2009; 23: 479-85.
155. Pode-Shakked N, Harari-Steinberg O, Haberman-Ziv Y, et al. Resistance or sensitivity of Wilms' tumor to anti-FZD7 antibody highlights the Wnt pathway as a possible therapeutic target. Oncogene 2011; 30: 1664-80.
156. Wang Z, Rao DD, Senzer N, et al. RNA interference and cancer therapy. Pharm Res 2011; 28: 2983-95.
157. Henry JC, Azevedo-Pouly AC, Schmittgen TD,. MicroRNA replacement therapy for cancer. Pharm Res 2011; 28: 3030-42.
158. Yeung ML, Jeang KT,. MicroRNAs and cancer therapeutics. Pharm Res 2011; 28: 3043-9.
159. Kasinski AL, Slack FJ,. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011; 11: 849-64.